Monoclonal Antibody to Inhibit IL33 for Autoimmune Disorders is under clinical development by Eli Lilly and Co and currently in Phase I for Autoimmune Disorders.
LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...